As WHO Rings COVID Zero Alarm, Study Says China Vaccination 'Insufficient'
52 Million Over 60 Still Unjabbed
The WHO calls the "COVID Zero" containment policy that Beijing is doubling down on "unsustainable," while a new study has shed light on the potential cost of moving away from cutting transmissions to mitigating disease.
You may also be interested in...
Following in the steps of Merck & Co. and GSK, Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in the country - but the US firm is going one step further.
Since October, reported cases of infectious respiratory diseases have been rising in China, prompting an information request from the WHO. However, no new types of pathogen or unusual clinical symptoms have been detected so far.
Topics in this latest Chinese-language podcast include the US approval of Chinese innovative drugs including Junshi’s anti-PD-1 antibody toripalimab, Sanofi’s deal with BioMap for AI-powered drug discovery, Chinese companies' third-quarter results and the Biden-Xi summit on the sidelines of APEC and its implications for bilateral regulatory dialog.